biostudies-literatureUnknown103(1)Calvez TAround one third of boys with severe hemophilia A develop inhibitors (neutralizing antibodies) against their therapeutic factor VIII product. This adverse effect may result in more life-threatening bleeding, disability, impaired quality of life, and costly care. We compared the incidence of inhibitors in boys treated with the three factor VIII products most used in France: one plasma-derived (Factane) and two recombinant products (Advate and Kogenate Bayer). A previously untreated cohort of patients was created in 1994 to investigate risk factors for inhibitor development. We selected boys with severe hemophilia A (factor VIII <1 IU/dL) first treated with one of the three factor VIII products studied. Details of product infusions, inhibitor assays and main fixed and time-varying inhibitor Haematologica179-189https://www.ebi.ac.uk/biostudies/studies/S-EPMC5777205biostudies-literatureAnalyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.PMC5777205Costa CLaurian YRafowicz ALutz PDerlon ADesprez DBerny KPouzol PCalvez TArdillon LGaillard SVolot FDutrillaux FBastenaire BTorchet MFGay VMonlibert BPautard BChambost HStieltjes NBerger CRospide PDurin-Assollant ABovet JPouille LOMilien VFiks SMBriquel MENyombe PRothschild CFaradji AValentin JBPaugy PRicard CLienhart ADeville ABeurrier PBayart STrossaert MSainte MIBertrand MADumesnil CDonadel CSNormand CFimbel BDoncarli AParquet APolack BCoatmelec BHassoun APouplard CFerry NGautier PVannier JPBehar CNegrier CGorde SBlanc LSchneider PSchoepfer CFressinaud EOunnoughene NAouba ASchved JFDemiguel VHarroche ALi-Thiao-Te VFrotscher BTarral EMeunier SPineau-Vincent FMoreau PVinciguerra CMacchi LOudot CWibaut BRyman ALambert TBiron-Andreani CMunzer MBenz-Lemoine EDalibard VLegrand FDonadio DRauch ARegina SGremy IGuerin VRobert VBiernat JDe LLHuguenin YThiercelin Legrand MFCostagliola DGoudemand JPan Petesch BSannie TBarro CBianchin MGembara PGuillet BFouassier MBarbay VStoven Cd'Oiron RCodine PPincemaille OToguyeni EFalaise CMonpoux FPeynet JGruel YAdjaoud DMicheau MGuerois CNavarro RDemay Yfor FranceCoag CollaboratorsBorg JYGuillaume YTintillier VCastet SHenni TDe REfalseAnalyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.Around one third of boys with severe hemophilia A develop inhibitors (neutralizing antibodies) against their therapeutic factor VIII product. This adverse effect may result in more life-threatening bleeding, disability, impaired quality of life, and costly care. We compared the incidence of inhibitors in boys treated with the three factor VIII products most used in France: one plasma-derived (Factane) and two recombinant products (Advate and Kogenate Bayer). A previously untreated cohort of patients was created in 1994 to investigate risk factors for inhibitor development. We selected boys with severe hemophilia A (factor VIII <1 IU/dL) first treated with one of the three factor VIII products studied. Details of product infusions, inhibitor assays and main fixed and time-varying inhibitor 2018-01-01T00:00:00Z2018 Jan2025-04-04T07:16:22.891Z2020-05-21T19:50:44ZS-EPMC57772052902591310.3324/haematol.2017.174706